COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:EVAX) (&#34;Evaxion&#34;), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting

EVAX

Evaxion concludes Annual General Meeting

Evaxion A/S Annual General Meeting Approves Key Proposals and Leadership

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:EVAX) (&amp;#34;Evaxion&amp;#34;), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Evaxion A/S announced the approval of its 2025 Annual Report and key board changes during its Annual General Meeting. The company, known for its AI-Immunology platform, continues to advance its vaccine pipeline, which could have significant implications for its market position as it seeks to address unmet medical needs.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Evaxion&#039;s 2025 Annual Report has been approved.</li><li>The Board of Directors&#039; proposals were successfully passed.</li><li>New Board member Jens Bitsch Nørhave is now included.</li><li>Evaxion specializes in AI-driven vaccine development.</li><li>The AI-Immunology platform enhances vaccine candidate discovery.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Evaxion A/S (EVAX)</strong>: Develops AI-driven vaccines, potential growth ahead.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits within &#039;Corporate Developments,&#039; as the approval of the Annual Report and board appointments are critical for the company&#039;s governance and operational strategy. Such developments are key for investor confidence and future fundraising efforts.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>AI-Immunology platform&#039;s success could lead to lucrative partnerships.</li><li>Board changes may facilitate faster decision-making in development.</li><li>Approval of annual reports sets a stable foundation for future financing.</li><li>Approval may boost investor confidence in upcoming clinical trials.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Evaxion held its Annual General Meeting on April 16, 2026.</li><li>The 2025 Annual Report received shareholder approval.</li><li>New board member Jens Bitsch Nørhave is appointed.</li><li>Evaxion employs over 40 experts in vaccine development.</li><li>The AI-Immunology platform supports rapid vaccine candidate development.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Evaxion presents a buy opportunity as AI-driven vaccines progress, potentially driving future growth within 12-18 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EVAX">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology&#x2122; platform, held its Annual General Meeting today at the company's offices.</p>  <p align="justify">The 2025 Annual Report was approved and the Board of Directors' proposals passed.</p>  <p align="justify">Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors.</p>  <p>Minutes from the meeting can be found on our <a href="https://www.globenewswire.com/Tracker?data=Iskt46yPcRpE4ZVl32ZRrPhd8OJEOFmWua3JpGS-CVWCaeB-EfAh8LKsXSxn4M4X-u42mPNU8oOwtS3tsWOsGi26VYcO9SOGrfEFnnhPf_H6Jvf_HasvwHNemzn1AKk6Njy4Z79nKRlD-Qv0QMPw8yZz2caiEpyKRggCJOCtDJfkPhGZpjQZacIOluTbOPwK" rel="nofollow" target="_blank">website</a>.</p>  <p><strong>Contact information </strong></p>  <p>Evaxion A/S <br></br>Mads Kronborg <br></br>Vice President, Investor Relations &amp; Communication <br></br>+45 53 54 82 96 <br></br><a href="https://www.globenewswire.com/Tracker?data=gwBQFwLTzGjM1cAmlXdAUiqbGYVHS3BksNANgu0giRqDwWQJvVgChs4oqedpHPhLzs01HLJ4rhYagWvYhenAfQ==" rel="nofollow" target="_blank">mak@evaxion.ai</a></p>  <p><strong>About </strong></p>  <p>Evaxion Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology&#x2122;. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.</p>  <p>With AI-Immunology&#x2122; we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.</p>  <p>We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients' lives by providing innovative and targeted treatment options. </p>  <p>For more information about Evaxion, AI-Immunology&#x2122; and our pipeline, please visit our <a href="https://www.globenewswire.com/Tracker?data=Iskt46yPcRpE4ZVl32ZRrCHdEbbZas4aUbgn5JUyzQZhJEI0eOfFTemFQ0TEu8QHRzb8EIHkNDE1WuI13eSeJg==" rel="nofollow" target="_blank">website</a>.</p>  <p><strong>Forward-looking statement </strong></p>  <p>This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, 2 including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at <a href="https://www.globenewswire.com/Tracker?data=wGCNFMu61NHI0eK5b7Nd-2TtA5nEQ3Aidq2lvlBwHOlkX6uRP0EdeDnNiekbhj8KAN9rDKqH5gpTP7eOIMbOdA==" rel="nofollow" target="_blank">www.sec.gov</a>. We do not assume any obligation to update any forward-looking statements except as required by law.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE3NjI3MSM0MDIzNzYwOTcjMjI1MjA4Nw=="></img> <br></br><img alt="" src="https://ml-eu.globenewswire.com/media/ODk1YzNjMGQtZjRjZi00ZTZmLTgzMTktZTFmM2M1Mjc4MzQ1LTEyNjM2NDAtMjAyNi0wNC0xNi1lbg==/tiny/Evaxion.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/19d0d69c-7f37-4d3b-8f26-2866d4ec3311"><img src="https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png" border="0" width="150" height="26" alt="Primary Logo"></img></a></p>

Evaxion A/S announced the approval of its 2025 Annual Report and key board changes during its Annual General Meeting. The company, known for its AI-Immunology platform, continues to advance its vaccine pipeline, which could have significant implications for its market position as it seeks to address unmet medical needs.

Evaxion concludes Annual General Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News